Post by otherottawaguy on Jun 30, 2022 9:20:23 GMT -5
(From another biotech board that I follow)
Is anyone tracking SANA and its work with cell transplants, been watching this one for a couple of years now, first mentions I am seeing about Type 1 impacts.
Regards,
OOG
SANA...Sana Biotechnology presents data at ISSCR 2022 annual meeting showing survival of transplanted hypoimmune iPSC-derived differentiated cell types without immunosuppression in non-human primates
"These data, demonstrating that three types of transplanted cells are able to survive and function in NHPs without immunosuppression, highlight the transformative potential of Sana's hypoimmune platform across a number of different cell types that can address a variety of diseases," said Steve Harr, Sana's President and Chief Executive Officer. "As an example, the use of allogeneic islet transplant has had limited success in treating type 1 diabetes due to morbidities from the necessary immunosuppression. In contrast, our data indicate that we successfully engineered HIP human pancreatic islet cells to evade immune recognition, and these cells persisted and normalized glucose levels in in vivo models. We are applying the hypoimmune platform to a number of programs in our pipeline, including SC291, our CD19 targeted allogeneic CAR T therapy for blood cancers, with a goal of an IND this year, and SC451, our islet cell program with a goal of an IND for the treatment of type 1 diabetes in 2023."
Is anyone tracking SANA and its work with cell transplants, been watching this one for a couple of years now, first mentions I am seeing about Type 1 impacts.
Regards,
OOG
SANA...Sana Biotechnology presents data at ISSCR 2022 annual meeting showing survival of transplanted hypoimmune iPSC-derived differentiated cell types without immunosuppression in non-human primates
"These data, demonstrating that three types of transplanted cells are able to survive and function in NHPs without immunosuppression, highlight the transformative potential of Sana's hypoimmune platform across a number of different cell types that can address a variety of diseases," said Steve Harr, Sana's President and Chief Executive Officer. "As an example, the use of allogeneic islet transplant has had limited success in treating type 1 diabetes due to morbidities from the necessary immunosuppression. In contrast, our data indicate that we successfully engineered HIP human pancreatic islet cells to evade immune recognition, and these cells persisted and normalized glucose levels in in vivo models. We are applying the hypoimmune platform to a number of programs in our pipeline, including SC291, our CD19 targeted allogeneic CAR T therapy for blood cancers, with a goal of an IND this year, and SC451, our islet cell program with a goal of an IND for the treatment of type 1 diabetes in 2023."
